alexion stock price

What is Alexion Pharmaceuticals'stock price?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN." What is Alexion Pharmaceuticals' stock price today? One share of ALXN stock can currently be purchased for approximately $182.50. How much money does Alexion Pharmaceuticals make?

How much is an ALXN stock worth?

One share of ALXN stock can currently be purchased for approximately $182.50. How much money does Alexion Pharmaceuticals make? Alexion Pharmaceuticals has a market capitalization of $40.34 billion and generates $6.07 billion in revenue each year.

How much is Alexion worth to AstraZeneca?

Each ADS represents one-half of one ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs). Based on AstraZeneca's reference average ADR price of $54.14, this implies a total consideration of $39 billion or $175 per share to Alexion’s shareholders.

What companies do other Alexion Pharmaceuticals investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), Walt Disney (DIS) and Visa (V).

See more

What happened to Alexion stock?

The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.

Who took over Alexion?

AstraZeneca has concluded the acquisition of US-based biopharmaceutical company Alexion Pharmaceuticals for a total consideration of $39bn or $175 per share.

When did AstraZeneca acquire Alexion?

The $39bn deal, announced in December 2020, is AstraZeneca's largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion's lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules.

Who owns Alexion Pharmaceuticals?

AstraZenecaAlexion Pharmaceuticals / Parent organizationAstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. Wikipedia

Who is buying Alexion?

AstraZeneca'sAstraZeneca's mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.

Why did AZ buy Alexion?

Now, AZ's buying Alexion for its knowledge in immune-mediated diseases. Alexion's portfolio includes Soliris and Ultomiris, which target C5, a key piece of the immune system. In addition, Alexion's pipeline includes 11 molecules targeting Factor D, FcRn and others.

Is Pfizer buying AstraZeneca?

Under the terms of the agreement, Pfizer will make an upfront payment of $550 million to AstraZeneca upon the close of the transaction and a deferred payment of $175 million in January 2019.

What is Alexion known for?

Alexion Pharmaceuticals, established in 1992, is a renowned global biopharmaceuticals company best known for its Soliris drug used for the treatment of rare disorders such as atypical hemolytic uremic syndrome (aHUS). It has been in the forefront of research into autoimmune diseases.

Is Alexion a takeover target?

Granted, Alexion Pharmaceuticals isn't the industry's most exciting acquisition target, but this deal will most likely work out well for investors in the long run.

Is Alexion publicly traded?

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases....Alexion Pharmaceuticals.TypeSubsidiaryTraded asNasdaq: ALXNIndustryPharmaceutical industryFounded1992FounderLeonard Bell12 more rows

Is Alexion Pharmaceuticals publicly traded?

(NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021.

When did Alexion buys Portola?

On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola's shareholders pursuant to Section 251(h) of the Delaware General Corporation Law. As a result of the merger, Portola became a wholly owned subsidiary of Alexion.

Who makes Ultomiris?

Please see the accompanying full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis. References: Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals Inc; 2019.

When was Alexion Pharmaceuticals founded?

1992, New Haven, CTAlexion Pharmaceuticals / FoundedFounded in 1992, Alexion became a publicly traded company four years later, trading on NASDAQ under the symbol ALXN. The company is set to move its global headquarters and research operations this year from Cheshire, CT, to New Haven, CT, where the company was founded.

What is Alexion known for?

Alexion Pharmaceuticals, established in 1992, is a renowned global biopharmaceuticals company best known for its Soliris drug used for the treatment of rare disorders such as atypical hemolytic uremic syndrome (aHUS). It has been in the forefront of research into autoimmune diseases.

Is Alexion Pharmaceuticals stock a Buy, Sell or Hold?

Alexion Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 7 buy ratings, 8 hold ratings, a...

What was the 52-week low for Alexion Pharmaceuticals stock?

The low in the last 52 weeks of Alexion Pharmaceuticals stock was 175.55. According to the current price, Alexion Pharmaceuticals is 103.96% away f...

What was the 52-week high for Alexion Pharmaceuticals stock?

The high in the last 52 weeks of Alexion Pharmaceuticals stock was 187.45. According to the current price, Alexion Pharmaceuticals is 97.36% away f...

What are analysts forecasts for Alexion Pharmaceuticals stock?

The 15 analysts offering price forecasts for Alexion Pharmaceuticals have a median target of 158.80, with a high estimate of 200.00 and a low estim...

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported...

How often does Alexion Pharmaceuticals pay dividends? What is the dividend yield for Alexion Pharmaceuticals?

Alexion Pharmaceuticals declared a quarterly dividend on Wednesday, October 27th. Investors of record on Monday, November 8th will be given a divid...

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people: Dr. Ludwig N. Hantson , CEO & Director (Age 58, Pay $4.25M) Dr. Aradhana...

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com . Ludwig Hantson has an approval rating of 75% among Alexion P...

Who are some of Alexion Pharmaceuticals' key competitors?

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Rege...

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Scien...

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ancora Advisors L...

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was purchased by a variety of institutional investors in the last quarter, including Ancora Advisors LLC. View insider buying and selli...

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Headlines

Was The Smart Money Right About Piling Into Microchip Technology Incorporated (MCHP)?

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alexion Pharmaceuticals stock.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

Who bought Alexion Pharmaceuticals?

Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion. Alexion Pharmaceuticals, Inc. ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will acquire the former.

Who is the billionaire investor who says it will produce the world's first trillionaires?

Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>.

What is Zacks research?

Zacks. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank.

Does AstraZeneca have a strong presence in oncology?

We note that AstraZeneca has a strong presence in oncology, cardiovascular, renal and metabolism, and respiratory diseases. Alexion’s shares have gained 11.9% in the year so far compared with the industry ’s growth 7.1%.

Does Alexion own 15% of the company?

Moreover, upon completion, Alexion’s shareholders will own 15% of the combined company .